Drug Discovery · Cambridge, MA · Founded 2020 · Privately Held (backing)
Operator of a clinical-stage biotechnology company intended to explore the full potential of alpha-emitting radioantibodies to treat cancer. Convergent Therapeutics is based in Cambridge, MA and was founded in 2020. Its last known valuation is $280 million. It has raised $130 million across 2 recorded rounds; the latest was a $22.2 million early-stage round in Jul 2024.
Last price · $/share
—
Implied valuation
$280.0M
Total raised
$130.0M
Last round
Early Stage VC
Jul 2024
No prints on record
No secondary trades in Convergent Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Convergent Therapeutics with a free account
·Watch Convergent Therapeutics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Convergent Therapeutics stock.
